WG
FULC icon

Winton Group’s Fulcrum Therapeutics FULC Stock Holding History

Winton Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,294
Closed -$162K – 1215
2025
Q4 		$162K Sell
14,294
-1,918
-12% -$19.5K 0.01% 847
2025
Q3 		$149K Buy
+16,212
New +$117K 0.01% 685
2025
Q1 		– Sell
-12,997
Closed -$61.1K – 712
2024
Q4 		$61.1K Sell
12,997
-31,204
-71% -$115K ﹤0.01% 587
2024
Q3 		$158K Buy
+44,201
New +$328K 0.01% 580

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Winton Group's FULC Position: Q1 2026 in Review

Winton Group sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 14,294 shares — an estimated $162K sold.

Winton Group first reported a position in FULC in Q3 2024 and held it in 4 quarters. The position peaked at $162K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Winton Group reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 14,294 Fulcrum Therapeutics shares in Q1 2026, an estimated $162K.
  • Winton Group first reported a position in Fulcrum Therapeutics in Q3 2024 and held it in 4 quarters.
  • Winton Group's Fulcrum Therapeutics position peaked at $162K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.